BridgePort Financial Solutions LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

BridgePort Financial Solutions LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,866 shares of the biopharmaceutical company's stock, valued at approximately $357,000.

A number of other hedge funds have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $28,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $31,000. Stephens Consulting LLC boosted its position in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in Gilead Sciences in the fourth quarter worth about $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of GILD traded up $2.67 during mid-day trading on Thursday, hitting $111.11. The company's stock had a trading volume of 5,596,339 shares, compared to its average volume of 7,722,822. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market capitalization of $138.21 billion, a PE ratio of 300.30, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The stock's 50-day moving average is $105.36 and its two-hundred day moving average is $100.57.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The firm's revenue for the quarter was down .3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,929 shares of company stock worth $5,644,780. Corporate insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GILD shares. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada upped their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.